PRINCIPLESOF CHOICEH. PYLORIFIRST-LINE THERAPY: CURRENT STATE OF PROBLEM


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The purpose of the review. Presentat the present levelprinciples of choice offirst-line regimensfor eradication of Helicobacter pylori. Show ingepidemiological aspectsof H. pylori resistance to antibiotics, included in the first linecircuit. On the basis of evidence presented various schemes of eradication, taking in to account the nature of the antimicrobialresistant, and the degreeofefficiency of elimination H. pylori. High lightspromisingways of improvingantimicrobial therapy H. pylori-infection.

全文:

受限制的访问

作者简介

A. Svistunov

I.M. Sechenov First Moscow State Medical University, Samara State Medical University

Email: osadchuk.mikhail@yandex.ru
Professor

M. Osadchuk

I.M. Sechenov First Moscow State Medical University, Samara State Medical University

Email: osadchuk.mikhail@yandex.ru
MD; Professor

A. Osadchuk

I.M. Sechenov First Moscow State Medical University, Samara State Medical University

Email: osadchuk.mikhail@yandex.ru
MD; Professor

参考

  1. Барышникова Н.В., Денисова Е.В., Корниенко Е.А. и др. Эпидемиологическое исследование резистентности Helicobacter pylori к кла- ритромицину у жителей Санкт-Петербурга с язвенной болезнью // Экспер. и клин. гастроэнтерол. - 2009; 5: 73-6
  2. Исаева Г.Ш. Резистентность Hp к антибактериальным препаратам и методы ее определения // Клин. микробиол. антимикроб. химиотер. - 2010; 12 (1): 57-66
  3. Кудрявцева Л.В. Состояние антибиотикорезистентности Helicobacter pylori в России // Экспер. и клин. гастроэнтерол. - 2003; 3: 4-5
  4. Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам // Мед. совет. - 2013; 10: 11-5
  5. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Актуальные возможности оптимизации антихеликобактерной терапии // Лечащий врач. - 2014; 4: 73-9
  6. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Антибиотикорезистентность Helicobacter pylori: от клинического значения до молекулярных механизмов // Лечащий врач. - 2014; 2: 34-40
  7. Маев И.В., Кучерявый Ю.А., Оганесян Т.С. и др. Какие схемы лечения инфекции Helicobacter pylori нужны нам сегодня? // Фарматека. - 2011; 11: 24-9
  8. Самсонов А.А., Андреев Д.Н., Гречушников В.Б. и др. Резистентность Helicobacter pylori к компонентам эрадикационной терапии и пути ее преодо- ления // Фарматека. - 2015; 2: 26-30
  9. Berning M., Krasz S., Miehlke S. Should quinolones come first in Helicobacter pylori therapy? // Ther. Adv. Gastroenterol. - 2011; 4: 103-14
  10. Cardarolli S., Rolfo A., Todros T. Helicobacter pylori and pregnancy-related disoders // World J. Gastroenterol. - 2014; 20 (3): 654-64
  11. Cetinkaya Z., Sezikli M., Güzelbulut F. et al. Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin // Helicobacter. - 2010; 15 (2): 143-7
  12. Chey W., Wong B. American College of Gastroenterology guideline on the management of Helicobacter pylori infection // Am. J. Gastroenterol. - 2007; 102: 1808-25
  13. Every A. Key host pathogen interactions for designing novel interventions against Helicobacter pylori // Trends Microbiol. - 2013; 21: 253-9
  14. Federico A., Gravina A., Miranda A. et al. Eradication of Helicobacter pylori infection: Which regimen first? // World J. Gastroenterol. - 2014; 20 (3): 665-72
  15. Federico A., Nardone G., Gravina A. et al. Efficacy of 5-day levofloxacin- containing concomitant therapy in eradication of Helicobacter pylori infection // Gastroenterology. - 2012; 143: 55-61
  16. Fischbach L., Evans E. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori // Aliment. Pharmacol. Ther. - 2007; 26 (3): 343-57
  17. Gatta L., Vakil N., Vaira D. et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequence therapy // BMG. - 2013; 7 (347): 4587
  18. Gill S., O’Brien L., Einarson T. et al. The safety of proton pump inhibitors (PPI) in pregnancy: a meta-analysis // Am. J. Gastroenterol. - 2009; 104: 1541-5
  19. Gisbert J., Calvel X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori // Clin. Exp. Gastroenterol. - 2012; 5: 23-34
  20. Gisbert J., Perez-Aisa А., Castro-Femandez М. еt al. Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin // Dig. Liver Dis. - 2010; 42 (287): 90
  21. Graham D., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance // Gut. - 2010; 59 (8): 1143-53
  22. Kim S., Lee S., Hyun J. et al. Comparative study of Helicobacter pylorieradication rates with 5-day quadruple «concominant» therapy and 7-day standard triple therapy // J. Clin. Gastroenterol. - 2013; 47: 21-4
  23. Malfertheiner P., Megraud F., O'Morain C. et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report // Gut. - 2012; 61 (5): 646-64
  24. Megraud F. Hp antibiotic resistance: prevalence, importance, and advances in testing // Gut. - 2004; 53: 1374-84
  25. Megraud F. Antimicrobial Resistance and Approaches to Treatment. In: P. Sutton, H. Mitchell eds. Helicobacter pylori in the 21st Century / Wallingford, UK: CABI, 2010
  26. Megraud F., Coenen S., Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. - 2013; 62 (1): 34-42
  27. Molina-Infante J., Romano M., Fernadez-Bermejo M. et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with rates of antibiotic resistance // Gastroenterology. - 2013; 145: 121-8
  28. Nishizawa T., Nishizawa Y., Yahagi N. et al. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis // J. Gastroenterol. Hepatol. - 2014; 29 (4): 20-4
  29. Perna F., Zullo A., Ricci C. et al. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance // Dig. Liver Dis. - 2007; 39 (11): 1001-5
  30. Polat Z., Kadayaifci A., Kantarcioglu M. et al. Comparison of levofloxacin- containing sequential and standard triple therapies for the eradication of Helicobacter pylori // Eur. J. Intern. Med. - 2012; 23: 165-8
  31. Riahizadeh S., Malekzadeh R., Agah S. et al. Sequential metronidazole- furazolidone or clarithromycin-furazolidone compared or clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial // Helicobacter. - 2010; 15: 497-504
  32. Romano M., Cuano A., Gravina A. et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial // Gut. - 2010; 59: 1465-70
  33. Sardarian H., Fakheri H., Hosseini V. et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial // Helicobacter. - 2013; 18 (2): 129-34
  34. Smith S., O’Morain C., McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance // World J. Gastroenterol. - 2014; 20 (29): 9912-21
  35. Sun Q., Liang X., Zheng Q. et al. High efficacy of 14-day triple therapy- based, bismuth-containing quadruple for initial Helicobacter pylori eradication // Helicobacter. - 2010; 15 (3): 233-8
  36. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment // Aliment. Pharmacol. Ther. - 2010; 32: 1069- 79
  37. Wang Z., Gao Q., Fang J. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium containing probiolic compound preparation in Helicobacter pylori eradication therapy // J. Clin. Gastroenterol. - 2013; 47: 25-32
  38. Zhang Y., Xia H., Zhuang Z. et al. Review article: «true» re-infection of Helicobacter pylori after successful eradication-worldwide annual rates, risk factors and clinical implication // Aliment. Pharmacol. Ther. - 2009; 29: 145-60
  39. Liang J., Li J., Han Y. et al. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial // Helicobacter. - 2012; 17 (6): 458-65
  40. Liou J., Chang C., Chen M. et al. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study // PLoS One. - 2015; 10 (5): 0124199
  41. Mahadevan U. Gastrointestinal medications in pregnancy // Best Pract. Res. Clin. Gastroenterol. - 2007; 21: 849-77
  42. Malfertheiner P., Bazzoli F., Delchier J. et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, methronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial // Lancet. - 2011; 377: 905-13
  43. Malfertheiner P., Megraud F., O’Morain C. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. - 2007; 56 (6): 772-81

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2015
##common.cookie##